The degree of visual enhancement in film and TV during recent years has been astounding. With Digital Cinema Initiatives 4K standard in theatres and 4K UHD at home, as well as a resurgence of 3D stereoscopic films in theatres using technologies like RealD 3D (NYSE: RLD), Dolby 3D (NYSE: DLB) and IMAX 3D (NYSE: IMAX), films look better than ever on the big, and small(er) screen. Similar innovations in the world of audio, led by top players such as Dolby, DTS (NASDAQ: DTSI) and Sony (NYSE: SNE), have allowed for an unprecedented level of acoustical richness and fidelity, resulting in viewer immersion horizons unimaginable to previous generations.

However, even as consumers start to get their hands on technologies like Oculus VR’s Oculus Rift head-mounted display, or the comparable virtual reality device developed in collaboration with Samsung (OTC: SSNLF), the Gear VR, there is one dimension of sense perception that has yet to see similar advancements: touch-feel. This is where pioneering haptic-tactile (of or relating to the sense of touch) technology developer Guitammer (OTCQB: GTMM) really shines, with a rapidly emerging brand presence driven by its portfolio of patented and patent pending broadcast technologies like the award-winning line of ButtKicker low frequency audio transducers. Haptic-tactile events experienced by viewers may have a visual and auditory portion to them, but Guitammer takes it that extra step and really puts viewers in the game, or lets them experience movies in a whole new way by letting them “feel” the impact of a hockey player getting checked into the boards, or the force of an explosion narrowly escaped by their favorite heroes.

Guitammer’s dynamic haptic event transmission technology is now coming to more theatres across the U.S. than ever before, on the back of a sweeping new deal with AMC Theatres (NYSE: AMC) which will expand the company’s installed footprint of ButtKicker-enabled theatres via 34 new deployments, more than doubling GTMM’s existing install base with AMC. President of GTMM, Mark Luden, was keen to point out how mounting order growth among theatres is driven by audience/proprietor receptivity to this innovative technology, which allows viewers to actually experience haptic events physically. As this new feature picks up steam, with more and more theatregoers actively seeking out this enticing and hitherto unexperienced dimension of film, the potential upside for GTMM as the leading hardware provider is quite significant.

This is especially true when one considers that, globally, total filmed entertainment revenue is estimated by PwC as being on-track to experience a CAGR of 4.1 percent through 2019, hitting upwards of $104 billion, led by hot markets like China (14.5 percent CAGR) and Latin America (Brazil 6.4 percent, Argentina 11.5 percent). In 2014 alone, the MPAA reported a $36.4 billion global box office take, with China experiencing a 34 percent jump over 2013’s figures, even as the number of cinema screens worldwide grew by 6 percent. With blockbusters like Star Wars:
The Force Awakens currently sitting on around $1.88 billion in worldwide gross, more than half of which came from the international market, the sky is indeed the limit for GTMM’s technology.

Westerville, Ohio-based Guitammer anticipates similarly robust growth moving forward in terms of adoption rates and estimates that some 2.5 million Americans will experience a ButtKicker enabled viewing after the company’s install base is bolstered by the new AMC additions. This end-user buzz feed system will in turn accelerate interest in Guitammer’s consumer grade solutions, driving sales of the company’s haptic-enabled broadcast services and hardware aimed at the home theatre market. The company’s technology is more musically accurate and considerably more powerful, as well as longer lasting, than competing voice coil shakers or other tactile devices, employing a magnetically suspended precision-guided piston that transfers vibration directly to whatever the unit’s housing is attached to.

Guitammer’s “4D Sports powered by ButtKicker” is a concept whose time has come and it is not hard to imagine this technology quickly proliferating out to the sports bar market. Because ButtKicker transducers accurately reproduce the feeling range of audio in a vastly more direct way than sound waves travelling through the air, and because when using headphones or speakers at a reduced volume the sound is completely isolated to the listener, the full range of possible implementations for this technology is immense. PwC estimates that global sports revenues were in the neighborhood of $145 billion last year (including factors like gate receipts), driven by rebounding TV advertising and an ongoing migration toward pay TV, as well as a return to the sponsorship space by financial services and automotive companies. It is no leap of faith to imagine ButtKicker devices in sporting arenas to help deliver a more realistic, front row seat experience to attendees at sporting events, even up in the cheap seats.

Delivering this level of powerful, concert-level audio directly to the listener, via a method that is driven by exacting capture and reproduction of remote haptic events, and in a fashion in which the user feels the event in perfect sync with (in the case of film) the audio and video – is something which has to be felt to be believed. To accurately comprehend the potential market for this technology, investors must experience it firsthand. Luckily, Guitammer has put together and maintains a Google Maps-based listing of venues where users can experience it for themselves. A listing which also illustrates how this incredible technology will soon be present on over 22,000 seats, in 11 countries, and in front of more than 100 screens worldwide.

Take a closer look by visiting http://www.guitammer.com/index, or head over to the company’s Facebook and Twitter feeds.

Moxian, Inc. (OTCQB: MOXC) earlier this week announced that its subsidiary, Moxian Technologies (Beijing) Co. Ltd., has entered into a partnership agreement with Xinhua New Media Culture Communication Co. Ltd. The arrangement enables Moxian to serve as the exclusive seller of advertising space for the Xinhua New Media App, Xinhua’s gaming platform. The five-year agreement states that Moxian will assist Xinhua with bolstering user retention by offering Mo-Coins and Mo-Points in exchange for interacting with advertisements within the app. Once the credits are acquired, users can log into the Moxian platform to redeem their rewards.

Tan Meng Dong James, Moxian’s CEO, stated, “This strategic cooperation agreement with Xinhua New Media Culture Communication Co. Ltd., a Xinhua Media affiliate, lays a solid foundation for Moxian’s future promotions and developments, while also gradually yet effectively driving the Moxian App into the Internet mainstream.”

The partnership fosters Moxian’s ability to have access to an impressive base of active members. Tan Meng Dong James’s recent statement notes that the app’s membership numbers are in the range of over 110 million registered users, including 10 million daily active users. As the exclusive reseller of advertising space for the app, Moxian is now poised to increase its visibility and market influence while simultaneously expanding its current base of customers.

The MOXC agreement with Xinhua initiates a key move toward maximizing on the market potential presented by its new Beijing subsidiary. This new revenue source puts Moxian in a strong position to take advantage of its expanded presence in the market. Meng Dong James added in his statement, “We look forward to the headway and potential this mutually advantageous deal provides both companies.”

Moxian, Inc. operates a social network online-to-offline platform that integrates social media and business for small- and medium-sized enterprises, primarily in China. MOXC products and services focus on creating interaction between users and merchant clients by allowing merchant clients to study consumer behavior. The company formerly operated under the name Moxian China, Inc. before changing its name to Moxian, Inc. in July 2015. Moxian, Inc. was founded in 2010 and is based in Shenzhen, China.

For more information, visit the company’s website at www.Moxian.com

Let us hear your thoughts: Moxian, Inc. Message Board

DreamTeamNetwork (DTN) is proud to announce its role as a platinum-level sponsor for the upcoming 2016 Disruptive Growth & Healthcare Conference, hosted by Source Capital Group, taking place in New York City February 10-11.

As a platinum sponsor, DTN has created and will manage a LinkedIn page specifically for the conference – the page will serve as a real-time hub where interested parties can take a look at what company is making its presentation and when, as well as a brief profile describing the specialty of each presenting company.

This one-of-a-kind conference will feature presentations from top executives of approximately 100 life science companies focused on solutions to unmet medical needs and growth companies with disruptive technologies and business models. The panels will cover regenerative medicine, immunotherapy, diagnostics, disruptive innovations and business models, disruptive holding companies, energy – clean tech, technology media & telecom (TMT), and a discussion regarding NOLs and rights offerings.

Attendees will include more than 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, source reps and their clients. If you’re not among those privy to attend, DTN has you covered.

Visit this link to follow the investor conference page and keep up-to-date on this exciting conference:

http://dtn.fm/linkedin-scg-conference

For more information visit www.sourcecapitalconference.com

Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) is journeying into a new era in battery manufacturing. The company is broadening its horizons in its quest to become a leader in every corner of the world battery market and using novel media and communications tools, including a new website (www.oakridgeglobalenergy.com), to spread the word about its moving message.

As a manufacturer, Oakridge is in an old-fashioned business, yet the corporation approaches its operations – developing, manufacturing, marketing and selling energy storage products – in unique ways. With an estimated market capitalization of USD $250,000,000, Oakridge is doing many things right.

Oakridge fully embraces the technology, vision and capability needed to execute its expansion strategies. Using the latest technology, the company designs, develops and manufactures the high-quality cells, batteries and energy storage systems that comprise its innovative ‘Made in the USA’ product portfolio. The portfolio includes multiple lithium-ion chemistries, technologies and form factors optimized for four high-demand target markets, including:

1. Motive applications, such as electric and hybrid electric fleet vehicles (especially golf cars and local area electric vehicles);
2. Remote control and portable devices (including medical devices);
3. Starter motor batteries for motorcycles, jet skis, snow mobiles and boats, as well as cars and trucks; and
4. Stationary living space power for domestic, commercial and grid applications (homes, businesses, RVs, boats and uninterruptable power supplies).

Generally, Oakridge’s power systems and batteries also have applications in the aerospace, marine, medical, military and telecom sectors.

Oakridge is a staple in the world of integrated energy storage solutions. It has been three decades since Oakridge was established (the company was incorporated in 1986), and the company continues to improve every facet of its business. While conducting a complete review and renovation of its business and products in 2014 and 2015, the company identified its investors’ and customers’ growing demand for information on Oakridge’s revolutionary energy storage technology. To address this need for more access, the company embarked on rebranding. Now, with new, best-in-class media and communication tools, Oakridge is providing its stakeholders with improved information and keeping them engaged in the company’s activities. The tools also provide Oakridge with a distinct point of differentiation over its competition in the Far East.

For more information, visit www.oakridgeglobalenergy.com

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

Cancer Genetics, Inc. (NASDAQ: CGIX) is focused on the development of personalized genetic testing for the detection of various cancers, with the goal of significantly increasing treatment efficacy while reducing healthcare costs. CGI’s scientific advisory board includes leaders in the areas of hematological malignancies, solid tumor cancers, pharmacogenomics, and clinical trials administration. The company’s growing patent base consists of molecular-focused patents for the diagnosis, prognosis, and risk stratification of difficult-to-treat cancers, based on what the company calls “unique algorithms that take into account multiple chromosomal regions associated with particular disease outcomes or treatment decision”.

CGI is heavily involved in the area of pharmacogenomics – determining the way genetics affects a patient’s drug response – to improve treatment and even help select trial populations for clinical testing. The company offers a number of pharmacogenomics testing services, including theranostic testing for various hematological and solid tumor cancers. In 2013, CGI helped form Oncospire Genomics as an equally owned joint venture with Mayo Clinic, designed to develop and commercialize NGS (Next Generation Sequencing) panels for unmet critical oncological needs. In 2014, CGI acquired Gentris, LLC, a pharmacogenomics testing, genotyping, and biorepository services company based in Raleigh, NC, with operations in China. That same year, the company also acquired India-based Bioserve Biotechnologies Pvt. Ltd., a leader in DNA related services in India.

Based in Rutherford, New Jersey, CGI also has operations in North Carolina and California, as well as in India and China. In addition, the company has research collaborations with cancer research and treatment leaders around the world, including:

• Beth Israel Deaconess Medical Center
• Cleveland Clinic
• Columbia University
• Groupe Hospitalier Pitié Salpétriêre, Paris
• Huntsman Cancer Institute, University of Utah
• Kamineni Hospital
• Keck Medicine of USC
• Mayo Clinic
• Memorial Sloan-Kettering Cancer Center
• Moffitt Cancer Center
• National Cancer Institute
• North Shore-Long Island Jewish Health System
• University of Alabama School of Medicine
• University of Iowa Cancer Center
• Westchester Medical Center at New York Medical College

CGI’s President and CEO is Panna Sharma, founder of TSG Partners, a specialty life sciences consultancy and advisory company, where he directed the company’s strategic initiatives and growth strategy, including various public and private company turnarounds, establishing several life science capital markets indices that are still used in the life science industry.

For more information, visit www.CancerGenetics.com.

The Clorox Company (NYSE: CLX) manufactures and markets consumer and professional products worldwide. The company operates through four segments: Cleaning, Household, Lifestyle, and International. Clorox is a global company with leading brands that have become household names, including its namesake bleach and cleaning products; Green Works naturally derived cleaning products; Ayudín and Poett home care products; Pine-Sol dilutable cleaner; Fresh Step cat litter; Kingsford charcoal; Hidden Valley and K.C. Masterpiece dressings and sauces; Brita water filtration products; Glad bags, wraps and containers; and Burt’s Bees natural personal care products.

Clorox manufactures products in more than two-dozen countries and markets them in more than 100 countries. The company offers laundry additives, including bleach products under the brand Clorox, as well as stain fighter and color booster products under the brand Clorox 2 and home care products under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands.

Clorox also provides naturally derived products under the Green Works brand name; and cleaning and disinfecting products under the Clorox, Dispatch, Aplicare, HealthLink, and Clorox Healthcare brands. In addition, the company offers plastic bags, wraps, and containers under the brand name Glad; cat litter products under the Fresh Step, Scoop Away, and Ever Clean brand names; and charcoal products under the Kingsford and Match Light brands.

In addition to the products mentioned above, Clorox provides dressings and sauces under the Hidden Valley, K.C. Masterpiece, and Soy Vay brand names; water-filtration systems and filters under the Brita brand; and natural personal care products under the Burt’s Bees brand name. Additionally, the company offers dust wipes under the brand name Clorox; facial products and lip crayons and balms under the Burt’s Bees brand; and scents under the Glad, OdorShield, and Gain brands. It also markets its products under the PinoLuz, Ayudin, Limpido, Clorinda, Poett, Mistolin, Lestoil, Bon Bril, Agua Jane, and Chux brands.

Clorox strives to make everyday life better in the parts of the world where it does business by giving back to its communities. Whether it’s contributing to disaster relief efforts through donations of Clorox regular bleach, teaching classes at local schools or funding education, arts and culture programs, Clorox is committed to helping restore, enrich and protect its communities.

For more information, please visit the company’s website at www.thecloroxcompany.com

Nike, Inc. (NYSE: NKE), headquartered in Beaverton, OR, is the world’s leading sportswear and sporting goods company, with a market cap approaching $100 billion. Founded in 1964 as Blue Ribbon Sports, and changing its name to NIKE in 1971, the company offers a full range of sports related clothing, accessories, and equipment through sports and department stores and shops worldwide, as well as directly to consumers over the Internet. Nike’s stated mission is “To bring inspiration and innovation to every athlete in the world”, adding that “if you have a body, you are an athlete”, the latter being a mantra used by legendary University of Oregon track and field coach, Bill Bowerman, who, along with Philip Knight, founded the company.

Philip H. Knight, a director of the company since 1968, is Chairman of the Board, and also served as company President for much of that time. Nike’s current CEO and President, Mark Parker, joined in 1979, using his experience as a competitive runner to design footwear for the company. Nike feels it has built its dominant position in the marketplace largely through its close connection with both the casual and professional sports community, and now serves the sports market on six continents. It continues to grow sales and market share.

In addition to its large Oregon headquarters, with over 8,000 employees, Nike has corporate locations in New York, Chicago, Los Angeles, Toronto, and Fort Worth. Its European headquarters is in the Netherlands, with operational and administrative centers in London, Paris, Frankfurt, Stockholm, Moscow, and several other locations. The Japan & Asia Pacific region is supported by key operations in Japan, Korea, India, Singapore, Malaysia, Indonesia, Vietnam, Australia, and other countries, while the Nike Greater China Campus, with nearly 2,000 employees, is located in Shanghai. Nike also employs more than 3,000 workers in Brazil, Argentina, Chile, Uruguay, Paraguay, Bolivia, and Mexico, and has operations in South Africa.

As a worldwide employer, Nike emphasizes its ongoing efforts to demand ethical working conditions from its suppliers and business partners, affirming detailed steps it continues to take to eliminate forced or bonded labor, and to incentivize changes that benefit workers throughout the supply chain. According to the company’s Standards for Compliance: “Nike uses third-party auditors to verify contracted factories are (in) compliance with laws. If a contracted factory is found to violate laws or Nike standards, it is responsible for improving performance against a master action plan. If the factory fails to make progress against that plan, they are subject to review and sanctions, including potential termination.”

For more information, visit http://investors.Nike.com/Home/default.aspx and http://about.Nike.com/

Alternet Systems, Inc. (OTCQB: ALYI) was recently identified as a “promising, undervalued emerging technology leader” in a report by Wall Street Corner. As a result, Wall Street Corner Special Report, which is hailed as the premier discovery site for promising, yet undiscovered small- and micro-cap stocks featuring opportunities in an ethical, professional and responsible manner, has engaged Caprock Research to initiate ongoing research coverage on the company. An initial report is expected to be released by the end of this month.

To view the initial release, visit http://www.wallstreetcornerreport.com/alyi-report

The report went on to praise Alternet’s history of successfully developing digital commerce technologies. Under its current management team, the company developed and sold a mobile wallet technology for $6 million, and Alternet is currently developing its next leading digital commerce technologies. With the world becoming increasingly dependent on technological conveniences and advances, Alternet is investing in verticals within the digital commerce space, transforming the legacy electronic payments infrastructure and developing advanced predictive data analytics applications for the mass consumer, as well as the telecommunications and financial industries.

Within the past two years, the company’s price per share (PPS) has climbed as high as $0.17, making its current PPS, which is under $0.02, well under the weighted two-year average PPS.

For more information, visit www.alternetsystems.com

Let us hear your thoughts: Alternet Systems, Inc. Message Board

Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a California-based biotechnology company and world leader in the sustainable manufacture of keyhole limpet hemocyanin (KLH), a protein used for stimulating and measuring immune response, has announced plans to form a joint venture with Neovacs S.A., a French biotechnology company focused on an active immunotherapy technology platform.

The joint venture will be for the manufacture of conjugated therapeutic vaccines based upon Stellar’s proprietary KLH protein, specifically to produce Neovacs’ Kinoid product candidates, including IFNa-Kinoid, and to potentially produce other KLH-based immunotherapies on behalf of third party customers. However, negotiations are not complete and will continue regarding details of the venture’s exact ownership and organization, though it is anticipated that initial ownership will be 70% with Neovacs and 30% with Stellar. The announcement was also careful to make clear that there can be no assurance the joint venture will be consummated or, if consummated, will achieve the expected results.

Stellar’s Chairman and CEO, Frank Oakes, said of the proposed venture: “We believe the proposed joint venture could be a very positive development for both Stellar and Neovacs. It would enable us to work together to ensure the successful development of IFNa-Kinoid at scale but, importantly, we anticipate building manufacturing infrastructure and expertise that could be offered to other developers of conjugate vaccines looking to transition their product candidates from clinical to commercial scale. For Stellar, this is an example of leveraging our KLH core business to expand our potential clinical and commercial opportunities.”

Neovacs CEO, Miguel Sieler, added: “We look forward to working with Stellar Biotechnologies to form this cooperative venture, as they are the leading supplier of KLH protein based on sustainable, scalable aquaculture techniques. Since KLH is a key component of IFNa-Kinoid, this venture is intended to support Neovacs as we work toward potential market launch, as well as bring added value in the field of KLH-Kinoid conjugate vaccines.”

For more information, visit www.StellarBiotech.com and http://ir.StellarBiotechnologies.com.

Earlier today, View Systems, Inc. (OTC: VSYM), a manufacturer and installer of non-invasive weapons detection systems for government and commercial use, announced it has entered into a definitive agreement to acquire Y.M. Advantage, Inc. (YMA), a private corporation engaged in the acquisition, development and management of medical clinics providing treatment for various medical issues. Through this acquisition, View Systems aims to achieve greater market penetration while promoting sustainable financial growth.

“As previously announced, our exploration and execution of M&A agreements are by no means an exit from our current focus of operations,” Gunther Than, chief executive officer of View Systems, stated in the news release. “After careful selection and due diligence, we’re excited to announce our acquisition of YMA, which will help View Systems gain traction in obtaining exposure, application and market penetration of our products.”

YMA’s business model focuses primarily on the acquisition of concierge, all-inclusive medical practices, particularly those relating to issues of male sexual dysfunction – including erectile dysfunction, testosterone replacement therapy and premature ejaculation. By targeting this niche in the medical community, YMA seeks to capitalize on current market trends that are being magnified by the aging population and a sharp rise in the prevalence of certain medical conditions.

Market statistics support YMA’s strategy. According to a report by Transparency Market Research, the increasing incidence of genitourinary diseases and a shifting preference toward a sedentary lifestyle represent lucrative opportunities in the male sexual dysfunction market moving forward. The company estimates the current U.S. market for erectile dysfunction at $6 billion, and aging baby boomers are expected to provide an expanding pool of prospective clients over the next decade.

In the past, major pharmaceutical companies Pfizer (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) have led the way in the male sexual dysfunction market with Viagra and Cialis, respectively, but projections suggest that this could be set to change in the coming years. While Viagra will maintain patent exclusivity until 2020, it is one of the final holdouts in the market. As exclusivities expire, industry data suggests that there will be an opportunity for new players to grab market share with innovative new drugs addressing medical conditions that are increasingly prevalent throughout the aging population. This should ensure that YMA’s targeted medical practices remain in high demand for the foreseeable future.

“Our board of directors consists of physicians who are well versed in the medical arena and have started and successfully operated clinics and medical practices,” continued Than. “They believe that this acquisition will dramatically enhance our revenue and provide for a wider ranging business practice.”

Look for View Systems to leverage the high demand for treatments related to male sexual dysfunction in order to promote strong financial growth. By acquiring YMA and maintaining its current focus of operations, the company becomes a diversified investment opportunity with tremendous upside for prospective shareholders.

For more information, visit www.viewsystems.com

Let us hear your thoughts: View Systems, Inc. Message Board